Levi & Korsinsky Alerts TransMedics Investors of Upcoming Class Action Lawsuit

Investors in TransMedics have been reminded by Levi & Korsinsky about the ongoing class action lawsuit that is currently pending. The deadline for investors to participate as lead plaintiffs in this case is April 15, 2025.

TransMedics is a company that focuses on developing and commercializing organ transplant systems. The class action lawsuit against TransMedics alleges that the company made false and misleading statements to investors. These statements purportedly concealed issues with the company’s OCS Lung device, which is used to support donor lungs during transport.

According to the lawsuit, TransMedics failed to disclose that its OCS Lung device experienced an increasing number of organ transplant failures. This led to the device being excluded from the FDA’s Expedited Access Pathway Program. The exclusion from this program would have had a significant impact on TransMedics’ business prospects and financial performance.

As a result of these alleged false and misleading statements, TransMedics’ stock price was artificially inflated. When the truth about the issues with the OCS Lung device came to light, the stock price dropped significantly. This caused investors who had purchased TransMedics stock at inflated prices to suffer financial losses.

Investors who purchased TransMedics stock between February 26, 2018, and December 4, 2019, are eligible to participate in the class action lawsuit. Those who wish to serve as lead plaintiffs must file a motion with the court by April 15, 2025.

Levi & Korsinsky is a national law firm that specializes in securities litigation. The firm is representing investors in the class action lawsuit against TransMedics. Investors who believe they may have a claim in this case are encouraged to contact Levi & Korsinsky for more information.

If you purchased TransMedics stock during the specified period and have suffered financial losses as a result of the alleged false and misleading statements, you may be eligible to participate in the class action lawsuit. It is important to act quickly, as the deadline to file a motion to serve as lead plaintiff is April 15, 2025.

Investors who choose to participate as lead plaintiffs in the class action lawsuit will have the opportunity to represent the interests of all investors affected by the alleged misconduct of TransMedics. By actively participating in the lawsuit, lead plaintiffs can seek to hold the company accountable for any financial losses suffered as a result of the alleged false statements.